Curasight Announces Preliminary Readout from its Phase 1 Clinical Trial with uTREAT in Aggressive Brain Cancer (Glioblastoma)

COPENHAGEN, Denmark, June 8, 2026 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company") (Spotlight: CURAS) announces encouraging preliminary readout from its Phase 1 clinical trial with uTR...